Skip to main
BLCO

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Bausch & Lomb is positioned for attractive fundamental growth because its core businesses are shifting toward higher-margin, differentiated products in dry eye, premium IOLs, and premium daily contact lenses, while the company’s broad portfolio of over 100 eye-care products supports share gains across end markets. MIEBO is a key driver, with durable prescription momentum and modeled revenue of $395MM in 2026 and $786MM in 2029, while XIIDRA’s gross-to-net improvement helps offset formulary pressure and sustain the pharma franchise. The surgical and contact lens businesses add further upside, as enVista Envy has resumed rapid growth after its recall, premium daily SiHy grew 23% y/y in 1Q'26 and 16% y/y in 2Q'26, and projected EBITDA of $1.2Bn reflects operating leverage and margin expansion potential.

Bears say

Bausch & Lomb is facing a negative setup because several core growth drivers appear vulnerable, including MIEBO missing its FY2026 guide, weaker-than-expected contact lens demand, and softer consumer sentiment that could pressure its OTC business. Its Surgical segment also looks exposed if premium IOL adoption slows, since that would weaken the product mix and compress margins, while the company’s broader eye-care portfolio still depends on legacy dry-eye treatments like RESTASIS that have slow onset and tolerability issues. In addition, the bioactive contact lens pipeline and next-generation innovation carry execution risk, and with contact lens wearers already showing a ~20-25% first-year discontinuation rate, the stock’s growth and margin expansion case looks fragile.

BLCO has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Buy based on their latest research and market trends.

According to 12 analysts, BLCO has a Buy consensus rating as of Oct 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.